Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2022-02-28
|
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurologic toxicities |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:drugClass |
gene therapy
|
| gptkbp:form |
cell suspension
|
| gptkbp:genericName |
gptkb:ciltacabtagene_autoleucel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carvykti
|
| gptkbp:indication |
multiple myeloma
|
| gptkbp:manufacturer |
gptkb:Janssen_Biotech
gptkb:Legend_Biotech |
| gptkbp:mechanismOfAction |
targets BCMA (B-cell maturation antigen)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
FDA approved
|
| gptkbp:storage |
refrigerated
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:bfsParent |
gptkb:CAR-T_cell
|
| gptkbp:bfsLayer |
6
|